Clinical Trial

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2024 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.
Trial Details
NCT Number NCT06566807
Lead Sponsor Huai'an First People's Hospital
Conditions Marginal Zone Lymphoma
Enrollment 51 participants
Start Date 2024-08-25
Primary Completion 2026-08-10 (estimated)
Study Completion 2028-08-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-22